Your browser doesn't support javascript.
loading
Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.
Chhabra, Akanksha; Ring, Aaron M; Weiskopf, Kipp; Schnorr, Peter John; Gordon, Sydney; Le, Alan C; Kwon, Hye-Sook; Ring, Nan Guo; Volkmer, Jens; Ho, Po Yi; Tseng, Serena; Weissman, Irving L; Shizuru, Judith A.
Afiliación
  • Chhabra A; Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Ring AM; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Weiskopf K; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Schnorr PJ; Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Gordon S; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Le AC; Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Kwon HS; Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Ring NG; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Volkmer J; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Ho PY; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Tseng S; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Weissman IL; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School
  • Shizuru JA; Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford,
Sci Transl Med ; 8(351): 351ra105, 2016 08 10.
Article en En | MEDLINE | ID: mdl-27510901
ABSTRACT
Hematopoietic stem cell (HSC) transplantation can cure diverse diseases of the blood system, including hematologic malignancies, anemias, and autoimmune disorders. However, patients must undergo toxic conditioning regimens that use chemotherapy and/or radiation to eliminate host HSCs and enable donor HSC engraftment. Previous studies have shown that anti-c-Kit monoclonal antibodies deplete HSCs from bone marrow niches, allowing donor HSC engraftment in immunodeficient mice. We show that host HSC clearance is dependent on Fc-mediated antibody effector functions, and enhancing effector activity through blockade of CD47, a myeloid-specific immune checkpoint, extends anti-c-Kit conditioning to fully immunocompetent mice. The combined treatment leads to elimination of >99% of host HSCs and robust multilineage blood reconstitution after HSC transplantation. This targeted conditioning regimen that uses only biologic agents has the potential to transform the practice of HSC transplantation and enable its use in a wider spectrum of patients.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Inmunoterapia Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Inmunoterapia Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos